Comparison of Oseltamivir and Oseltamivir Carboxylate Concentrations in Venous Plasma, Venous Blood, and Capillary Blood in Healthy Volunteers-Reference-Cited by-同舟云学术

Comparison of Oseltamivir and Oseltamivir Carboxylate Concentrations in Venous Plasma, Venous Blood, and Capillary Blood in Healthy Volunteers

Published:2013-06 Issue:6 Volume:57 Page:2858-2862
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Instiaty Insti¹²,Lindegardh Niklas²³,Jittmala Podjanee²,Hanpithakpong Warunee²,Blessborn Daniel²³,Pukrittayakamee Sasithon¹,White Nicholas J.²³,Tarning Joel²³

Affiliation:

1. Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

2. Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand

3. Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom

Abstract

ABSTRACT Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood, and capillary blood taken simultaneously from 24 healthy volunteers. Median (range) venous-blood-to-plasma ratios were 1.42 (0.920 to 1.97) for oseltamivir and 0.673 (0.564 to 0.814) for oseltamivir carboxylate. Capillary blood/venous plasma ratios were 1.32 (0.737 to 3.16) for oseltamivir and 0.685 (0.502 to 1.34) for oseltamivir carboxylate. Oseltamivir concentrations in venous and capillary blood were similar. Oseltamivir carboxylate showed a time-dependent distribution between venous and capillary blood.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02408-12

Reference14 articles.

1. Antiviral agents for the treatment and chemoprophylaxis of influenza—recommendations of the Advisory Committee on Immunization Practices (ACIP);Fiore AE;MMWR Recommend. Rep,2011

2. The Pharmacokinetics and Tolerability of the Oral Neuraminidase Inhibitor Oseltamivir (Ro 64-0796/GS4104) in Healthy Adult and Elderly Volunteers

3. Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers

4. Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802

5. Development and validation of a liquid chromatographic–tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting complex kidney drug handling using a physiologically‐based pharmacokinetic model informed by biomarker‐estimated secretory clearance and blood flow;Clinical and Translational Science;2023-11-20

2. Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development;The AAPS Journal;2023-11-16

3. Land O’Lakes Workshop on Microsampling: Enabling Broader Adoption;The AAPS Journal;2020-10-23

4. Application of physiologically based pharmacokinetic modeling to predict drug disposition in pregnant populations;Biopharmaceutics & Drug Disposition;2017-07-13

5. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants;Drug Metabolism and Disposition;2016-11-28